Vadim V. Shindyapin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Vadim V. Shindyapin has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
A. A. Shatilova
Almazov National Medical Research Centre; Institute of Medicine and Life Sciences, I. Kant Baltic Federal University
1 shared publication- Anastasia S. Yakovleva
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia
1 shared publication Anna Artemyeva
Pathology department, Federal State Budgetary Institution "National Medical Research Center of Oncology named after N.N. Petrov" of the Ministry of Health of the Russian Federation, Saint Petersburg, Russia
1 shared publication- Daniil Shevyrev
Sirius University of Science and Technology
1 shared publication - Daria A. Bogdanova
Division of Immunobiology and Biomedicine, Sirius University of Science and Technology, 354349 Sirius, Russia
1 shared publication - Daria A. Bogdanova
Department of Genetics and Life Sciences, Sirius University of Science and Technology, 354340 Sirius, Russia
1 shared publication
Latest Publications
- Open Access
- 25 July 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1481726
Vasculogenic mimicry in non-small cell lung cancer: a systematic review
Vasculogenic mimicry (VM), a non-endothelial tumor blood supply mechanism linked to poor prognosis in various cancers, requires consolidated prognostic evaluation in non-small cell lung cancer (NSCLC). This systematic review synthesized evidence on VM’s association with survival outcomes (OS, DFS, PFS) in NSCLC patients. Following PRISMA-ScR guidelines, PubMed and Google Scholar were searched, identifying 19 eligible studies (all in Chinese populations) using immunohistochemistry (CD31/CD34-PAS) for VM detection. Eighteen studies found VM presence (prevalence 13.6%–45.2%) significantly associated with worse survival. Multivariate analyses identified VM as an independent negative prognostic factor, increasing mortality risk (HR 1.542–2.542) and progression risk (HR 2.1–2.4). However, critical limitations included exclusive focus on Asian cohorts, universal retrospective design, inconsistencies and potential artifacts in VM detection, and statistical issues (misreported risk measures, discordant data). While VM correlates with reduced survival in NSCLC, suggesting potential prognostic utility, these limitations - particularly ethnic homogeneity, retrospective bias, methodological heterogeneity, and statistical errors - preclude definitive conclusions. Future prospective studies with standardized VM assessment and diverse populations are essential for validation.
- 25 July 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1481726
Open AccessVasculogenic mimicry in non-small cell lung cancer: a systematic review
Vasculogenic mimicry (VM), a non-endothelial tumor blood supply mechanism linked to poor prognosis in various cancers, requires consolidated prognostic evaluation in non-small cell lung cancer (NSCLC). This systematic review synthesized evidence on VM’s association with survival outcomes (OS, DFS, PFS) in NSCLC patients. Following PRISMA-ScR guidelines, PubMed and Google Scholar were searched, identifying 19 eligible studies (all in Chinese populations) using immunohistochemistry (CD31/CD34-PAS) for VM detection. Eighteen studies found VM presence (prevalence 13.6%–45.2%) significantly associated with worse survival. Multivariate analyses identified VM as an independent negative prognostic factor, increasing mortality risk (HR 1.542–2.542) and progression risk (HR 2.1–2.4). However, critical limitations included exclusive focus on Asian cohorts, universal retrospective design, inconsistencies and potential artifacts in VM detection, and statistical issues (misreported risk measures, discordant data). While VM correlates with reduced survival in NSCLC, suggesting potential prognostic utility, these limitations - particularly ethnic homogeneity, retrospective bias, methodological heterogeneity, and statistical errors - preclude definitive conclusions. Future prospective studies with standardized VM assessment and diverse populations are essential for validation.
- Open Access
Myeloid Cell Mobilization and Recruitment by Human Mesothelioma in NSG-SGM3 Mice
Malignant pleural mesothelioma is a neoplasm that is often detected late due to nonspecific symptoms. This study utilized NSG-SGM3 mice to examine interactions between a human-derived mesothelioma reporter cell line (MZT-Luc2-mCherry) and the host’s myeloid compartment. Tumor growth was assessed using optical tomography, while cytokine/chemokine production was analyzed via multiplex assay. Histological and immunohistochemical analyses validated the epithelioid mesothelioma phenotype. In vitro mesothelioma cells secreted factors associated with myeloid cell chemoattraction and functions supporting the previously reported myeloid-biased secretory phenotype. In line with this, post-engraftment analysis revealed increased neutrophil-like Ly6G+ populations and decreased Ly6C+ inflammatory monocytes in the blood of tumor-bearing mice. Significant Ly6G+ cell infiltration was observed in the tumor, while CD11b+ myeloid cells were localized primarily in the tumor periphery. Tumor lysates showed increased levels of neutrophil chemoattractants and G-CSF, suggesting a previously not reported role of neutrophils in mesothelioma progression. This novel model provides a platform for studying mesothelioma–host interactions, focusing on the myeloid compartment. It may also serve as a tool to facilitate the development of new therapeutic strategies targeting myeloid cell-mediated mechanisms in mesothelioma.
Open AccessMyeloid Cell Mobilization and Recruitment by Human Mesothelioma in NSG-SGM3 Mice
Malignant pleural mesothelioma is a neoplasm that is often detected late due to nonspecific symptoms. This study utilized NSG-SGM3 mice to examine interactions between a human-derived mesothelioma reporter cell line (MZT-Luc2-mCherry) and the host’s myeloid compartment. Tumor growth was assessed using optical tomography, while cytokine/chemokine production was analyzed via multiplex assay. Histological and immunohistochemical analyses validated the epithelioid mesothelioma phenotype. In vitro mesothelioma cells secreted factors associated with myeloid cell chemoattraction and functions supporting the previously reported myeloid-biased secretory phenotype. In line with this, post-engraftment analysis revealed increased neutrophil-like Ly6G+ populations and decreased Ly6C+ inflammatory monocytes in the blood of tumor-bearing mice. Significant Ly6G+ cell infiltration was observed in the tumor, while CD11b+ myeloid cells were localized primarily in the tumor periphery. Tumor lysates showed increased levels of neutrophil chemoattractants and G-CSF, suggesting a previously not reported role of neutrophils in mesothelioma progression. This novel model provides a platform for studying mesothelioma–host interactions, focusing on the myeloid compartment. It may also serve as a tool to facilitate the development of new therapeutic strategies targeting myeloid cell-mediated mechanisms in mesothelioma.
- Open Access
Senolytic Vaccines from the Central and Peripheral Tolerance Perspective
Preventive medicine has proven its long-term effectiveness and economic feasibility. Over the last century, vaccination has saved more lives than any other medical technology. At present, preventative measures against most infectious diseases are successfully used worldwide; in addition, vaccination platforms against oncological and even autoimmune diseases are being actively developed. At the same time, the development of medicine led to an increase in both life expectancy and the proportion of age-associated diseases, which pose a heavy socio-economic burden. In this context, the development of vaccine-based approaches for the prevention or treatment of age-related diseases opens up broad prospects for extending the period of active longevity and has high economic potential. It is well known that the development of age-related diseases is associated with the accumulation of senescent cells in various organs and tissues. It has been demonstrated that the elimination of such cells leads to the restoration of functions, rejuvenation, and extension of the lives of experimental animals. However, the development of vaccines against senescent cells is complicated by their antigenic heterogeneity and the lack of a unique marker. In addition, senescent cells are the body’s own cells, which may be the reason for their low immunogenicity. This mini-review discusses the mechanisms of central and peripheral tolerance that may influence the formation of an anti-senescent immune response and be responsible for the accumulation of senescent cells with age.
Open AccessSenolytic Vaccines from the Central and Peripheral Tolerance Perspective
Preventive medicine has proven its long-term effectiveness and economic feasibility. Over the last century, vaccination has saved more lives than any other medical technology. At present, preventative measures against most infectious diseases are successfully used worldwide; in addition, vaccination platforms against oncological and even autoimmune diseases are being actively developed. At the same time, the development of medicine led to an increase in both life expectancy and the proportion of age-associated diseases, which pose a heavy socio-economic burden. In this context, the development of vaccine-based approaches for the prevention or treatment of age-related diseases opens up broad prospects for extending the period of active longevity and has high economic potential. It is well known that the development of age-related diseases is associated with the accumulation of senescent cells in various organs and tissues. It has been demonstrated that the elimination of such cells leads to the restoration of functions, rejuvenation, and extension of the lives of experimental animals. However, the development of vaccines against senescent cells is complicated by their antigenic heterogeneity and the lack of a unique marker. In addition, senescent cells are the body’s own cells, which may be the reason for their low immunogenicity. This mini-review discusses the mechanisms of central and peripheral tolerance that may influence the formation of an anti-senescent immune response and be responsible for the accumulation of senescent cells with age.
- Open Access
- 27 July 2024
- Published by SPb RAACI in Medical Immunology (Russia)
- Vol. 26 (4) , 827-834
Increase in serum IL-4 in response to venetoclax therapy in xenograft models of acute myeloid leukaemia
Despite significant progress in basic and preclinical research into acute myeloid leukaemia (AML), the five-year survival rate for patients with AML remains poor, highlighting the urgent need for new combination therapies. Over the past decade, increased attention has been focused on identifying suitable immunotherapeutic strategies to combat AML, in particular targeting leukaemia cells and their precursors with cytokines. Targeted therapy is also an established approach for the treatment of AML. However, with the increasing number of treatment options, there are challenges in understanding how to select the most effective therapy and how to combine different drugs. Venetoclax is a targeted agent, a potent and highly selective inhibitor of B cell lymphoma protein-2 (BCL-2), one of the cell’s major anti-apoptotic proteins. Research into approaches to improve the treatment of AML remains challenging due to the limitations of experimental models. Despite improvements in ex vivo culture protocols, in vivo models remain the only way to study the inherently heterogeneous nature of AML and the influence of the microenvironment on leukaemia development. In our study, we show that in a xenograft mouse model of acute myeloid leukaemia in mice of the NSG-SGM3 line, there is an increase in serum IL-4 in response to venetoclax therapy. IL-4 has previously been shown to induce apoptosis in AML cells. These data provide new perspectives for the use of strategies based on the synergism of venetoclax and IL-4 in inducing apoptosis. The data also show an increase in serum human MCP-1 levels upon engraftment of OCI-AML-2 leukaemia cells in the serum of xenografted mice, which decreases after venetoclax therapy and may serve as a prognostic marker for the success of ongoing therapy. An obvious advantage of xenograft models in mice was the ability to separate the expression and secretion of murine cytokines and chemokines that determine the microenvironmental response from the cytokine profile of the human tumor cells themselves. Overall, our data suggest additional functional features of venetoclax action on tumor cells through the regulation of cytokine secretion and the prospect of using the immunodeficient mouse line NSG-SGM3 to test new approaches to the treatment of AML.
- 27 July 2024
- Published by SPb RAACI in Medical Immunology (Russia)
- Vol. 26 (4) , 827-834
Open AccessIncrease in serum IL-4 in response to venetoclax therapy in xenograft models of acute myeloid leukaemia
Despite significant progress in basic and preclinical research into acute myeloid leukaemia (AML), the five-year survival rate for patients with AML remains poor, highlighting the urgent need for new combination therapies. Over the past decade, increased attention has been focused on identifying suitable immunotherapeutic strategies to combat AML, in particular targeting leukaemia cells and their precursors with cytokines. Targeted therapy is also an established approach for the treatment of AML. However, with the increasing number of treatment options, there are challenges in understanding how to select the most effective therapy and how to combine different drugs. Venetoclax is a targeted agent, a potent and highly selective inhibitor of B cell lymphoma protein-2 (BCL-2), one of the cell’s major anti-apoptotic proteins. Research into approaches to improve the treatment of AML remains challenging due to the limitations of experimental models. Despite improvements in ex vivo culture protocols, in vivo models remain the only way to study the inherently heterogeneous nature of AML and the influence of the microenvironment on leukaemia development. In our study, we show that in a xenograft mouse model of acute myeloid leukaemia in mice of the NSG-SGM3 line, there is an increase in serum IL-4 in response to venetoclax therapy. IL-4 has previously been shown to induce apoptosis in AML cells. These data provide new perspectives for the use of strategies based on the synergism of venetoclax and IL-4 in inducing apoptosis. The data also show an increase in serum human MCP-1 levels upon engraftment of OCI-AML-2 leukaemia cells in the serum of xenografted mice, which decreases after venetoclax therapy and may serve as a prognostic marker for the success of ongoing therapy. An obvious advantage of xenograft models in mice was the ability to separate the expression and secretion of murine cytokines and chemokines that determine the microenvironmental response from the cytokine profile of the human tumor cells themselves. Overall, our data suggest additional functional features of venetoclax action on tumor cells through the regulation of cytokine secretion and the prospect of using the immunodeficient mouse line NSG-SGM3 to test new approaches to the treatment of AML.